Bavencio(avelumab)PD-L1抗体

Bavencio(Avelumab) belongs to PD-L1 antibody, which blocks the interaction between cancer cell PD-L1 and its receptors PD-1 and B7.1, thus activating human immune function, distinguishing cancer cells from normal cells, and inducing immune function to inhibit the proliferation of cancer cells.

[Indications of Bavencio(Avelumab)PD-L1 antibody]

Bavencio(Avelumab) is suitable for adults and children over 12 years old with metastatic Merkel cell carcinoma (MCC) and patients with metastatic urothelial carcinoma (UC) who have received platinum chemotherapy.

[Bavencio(Avelumab)PD-L1 antibody specification]

This product is an injection with the specification of 200mg/10mL(20mg/mL).

[Usage and dosage of Bavencio(Avelumab)PD-L1 antibody]

This product is infused once every 2 weeks, with a dose of 10mg/kg according to body weight each time, which lasts for 60 minutes.

[Warning and Precautions of Bavencio(Avelumab)PD-L1 Antibody]

(1) Immune-mediated pneumonia: suspension of medication for moderate pneumonia; Permanent termination of severe, life-threatening or recurrent moderate pneumonia.

(2) Immune-mediated hepatitis: monitoring the changes of liver function. Suspension of medication for moderate hepatitis; Severe or life-threatening hepatitis is permanently terminated.

(3) Immune-mediated colitis: suspension of medication for moderate or severe colitis; Permanent termination of life-threatening or recurrent severe colitis.

(4) Immune-mediated endocrine diseases: severe or life-threatening endocrine diseases are suspended.

(5) Immune-mediated glomerulonephritis and renal insufficiency: stop taking drugs for moderate or severe nephritis and renal insufficiency; Life-threatening nephritis or renal insufficiency is permanently terminated.

(6) Infusion-related reactions: Suspend or slow down the infusion rate for mild or moderate infusion-related reactions. Severe or life-threatening transfusion related reactions stop infusion and permanently terminate BAVENCIO.

(7) Embryo-fetal toxicity: BAVENCIO may cause fetal harm. Suggestions on the potential risks of the fetus and the use of effective contraception.